{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T14:20:10Z","timestamp":1784557210099,"version":"3.55.0"},"reference-count":0,"publisher":"Bioscientifica","issue":"2","content-domain":{"domain":["erc.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,2,1]]},"abstract":"\n 177<\/jats:sup>\n Lu-Dotatate is increasingly used in patients with advanced neuroendocrine tumour (NET). However, few prognostic markers are available to stratify progression-free survival (PFS) of patients who received\n 177<\/jats:sup>\n Lu-Dotatate. Clinicopathological data including baseline circulating biomarkers of patients with advanced NET who received\n 177<\/jats:sup>\n Lu-Dotatate were routinely collected and were retrospectively analysed. Continuous variables were normalized by dividing them by their upper normal limits. The whole data set was randomly divided into a training set and a validation set. Univariate and multivariate logistic regression analyses were used to identify independent markers and to develop a scoring model to predict treatment failure at 1 year. In total, 195 patients were included. Elevated baseline chromogranin A (CgA), normal creatinine and previous chemotherapy were three risk factors independently associated with 1-year treatment failure. By combining these risk factors, a scoring model was developed which could accurately predict 1-year treatment failure both in the training set (area under curve, AUC, 0.813; 95% CI, 0.731\u20130.895;\n P<\/jats:italic>\n < 0.001) and in the validation set (AUC, 0.816; 95% CI, 0.644\u20130.968;\n P<\/jats:italic>\n < 0.001). After selecting a score of 29.7 as the cut-off value of the scoring model, patients could be stratified into two groups namely low-risk and high-risk with significantly different 1-year treatment failure rate, PFS and overall survival (OS;\n P<\/jats:italic>\n < 0.001) both in the training set and validation set. In conclusion, baseline CgA, creatinine level and previous chemotherapy were independently associated with 1-year treatment failure of patients with advanced NET who received\n 177<\/jats:sup>\n Lu-Dotatate and the scoring model and prognostic stratification based on these markers could accurately predict 1-year treatment failure, PFS and OS.\n <\/jats:p>","DOI":"10.1530\/erc-21-0248","type":"journal-article","created":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T09:36:20Z","timestamp":1641288980000},"page":"111-120","update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-8","source":"Crossref","is-referenced-by-count":7,"title":["Prognostic stratification for patients with neuroendocrine tumours receiving 177Lu-Dotatate"],"prefix":"10.1530","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3510-5921","authenticated-orcid":true,"given":"Luohai","family":"Chen","sequence":"first","affiliation":[{"name":"1Neuroendocrine Tumour Unit, ENETS Centre of Excellence, Royal Free London NHS Foundation, London, UK"},{"name":"2Department of Gastroenterology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China"},{"name":"3Institute for Liver and Digestive Disease, Royal Free Hospital, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gopinath","family":"Gnanasegaran","sequence":"additional","affiliation":[{"name":"4Department of Nuclear Medicine, Royal Free London NHS Foundation, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalvinder","family":"Mandair","sequence":"additional","affiliation":[{"name":"1Neuroendocrine Tumour Unit, ENETS Centre of Excellence, Royal Free London NHS Foundation, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos","family":"Toumpanakis","sequence":"additional","affiliation":[{"name":"1Neuroendocrine Tumour Unit, ENETS Centre of Excellence, Royal Free London NHS Foundation, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martyn","family":"Caplin","sequence":"additional","affiliation":[{"name":"1Neuroendocrine Tumour Unit, ENETS Centre of Excellence, Royal Free London NHS Foundation, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2886-9691","authenticated-orcid":true,"given":"Shaunak","family":"Navalkissoor","sequence":"additional","affiliation":[{"name":"4Department of Nuclear Medicine, Royal Free London NHS Foundation, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","container-title":["Endocrine-Related Cancer"],"original-title":[],"link":[{"URL":"https:\/\/erc.bioscientifica.com\/view\/journals\/erc\/29\/2\/ERC-21-0248.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/erc.bioscientifica.com\/downloadpdf\/journals\/erc\/29\/2\/ERC-21-0248.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T13:56:09Z","timestamp":1784555769000},"score":1,"resource":{"primary":{"URL":"http:\/\/journals.bioscientifica.com\/erc\/article\/29\/2\/111-120\/25598"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,1]]},"references-count":0,"journal-issue":{"issue":"2"},"URL":"https:\/\/doi.org\/10.1530\/erc-21-0248","relation":{},"ISSN":["1351-0088","1479-6821"],"issn-type":[{"value":"1351-0088","type":"print"},{"value":"1479-6821","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,1]]}}}